×

你想链接到这个吗?External Siteand leave Amgen.com?

您现在要离开Amgen的网站。amgen.takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

你想链接到这个吗?External Siteand leave Amgen.com?

您现在要离开Amgen的网站。amgen.takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

你想链接到这个吗?External Siteand leave Amgen.com?

您现在要离开Amgen的网站。amgen.takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

你想链接到这个吗?External Siteand leave Amgen.com?

您现在要离开Amgen的网站。amgen.takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

研究和发展战略

为了支持AMGEN的服务患者使命,研发组织旨在发现,开发和提供改良药物,这些药物解决了解决死亡和残疾的主要原因,致力于满足尽可能多的患者的需求。为实现这一愿景,我们需要充分利用快速科学进步和新技术所产生的机会。生物技术和数据科学正在致盲速度推进,开辟了巨大的新可能性。与此同时,行业内的竞争正在加剧,并访问药物的障碍是众多和陡峭的。

为了跟上这些迅速改变的机会和挑战,AMGEN采用了一种动态的研发战略。它旨在:

  • Preserve the core elements of our legacy strategy, including a focus on large effect sizes in serious illnesses and a Biology First approach to understanding disease and designing new potential therapies.
  • 指导我们制作聪明,综合的选择,反映了世界今天的世界。
  • 定位我们迅速适应,因为我们的机会和挑战进化了。

amgen.’s scientific success has been rooted in a unique “triple threat” capability that includes world-class human genetics, a deep understanding of disease biology, and the molecular engineering expertise needed to design the right drug for the right target. By building on Amgen’s long-standing strengths in science and biotechnology, we’re confident we can deliver solutions that patients need and society will embrace.

— David M. Reese, Executive Vice President, Research and Development

我们的愿景

Benefit patients and societies through transformative medicines.

我们的优先事项

Improve our success rates。将我们的人民和投资更加集中在最有可能导致新疗法的活动中。

减少循环时间。项目的标准时间表12至14岁从项目开始到毒品批准是不可行的。Amgen已经将其药物开发时间表减少了大约三年,但仍有充足的改进空间。

启用访问和使用。获得新疗法的监管批准只是战斗的一半。最终,只有一个公制事项:是需要氨的药物实际上的患者吗?

我们的战略要求

在创新研究平台上进行重点投资

  • Focus research investments in cardiometabolic, inflammation and cancer therapeutic areas. Rapidly expand the scale and diversity of our human genetic platform.
  • 扩展我们的人力资源,包括蛋白质组学,转录组织和联合数据,以产生更深入的疾病生物学。
  • 利用我们的实力在分子工程中扩大当前药物平台的成功,包括BITE®分子,以及先驱新颖的方式,以解决现在被视为不申请的目标。

Innovate in Clinical Development

  • Reduce the durations and cost of clinical trials and improve success rates through greater use of modelling and simulation, adaptive designs, and real world evidence.
  • 使用遗传和常规来设计较大和更快的研究,以识别患者可能从新疗法中受益的患者。

在所有药物开发的所有阶段访问和使用

  • Ensure that representatives from our medical, clinical development, commercial, and manufacturing functions are partnering with research teams very early in each drug discovery program to define the attributes a new medicine will need to gain future access and use.
  • 利用我们的全球医疗组织及其外部网络合作者网络,以产生对我们的药物开发团队必须产生的证据的见解,以支持访问和使用。
  • Invest in biomarkers, diagnostics, and other tools that can enhance the value of our medicines and support Amgen’s commitment to empower doctors to go beyond a traditional “one size fits all” approach to treat patients in a more precise, personalized way.

我们的战略推动者

  • 通过挑战我们的工作方式,加快决策,加快决策,为自由资源提供更好的生产力来实现我们的科学和创新,以使我们的长期和成功致力于在研发方面的所有方面持续提高和运营效率。
  • The foundation for our past and future success is our people – they form the foundation for all we do. We will continue to build an R&D culture that recruits, develops, and retains the best talent excited by the opportunities arising from rapid scientific progress and new technologies to push the boundaries of science as part of a collaborative team vested in a collective accountability for our success.